• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Vaccine Market by Technology & Types, Various Classes & Indications - Global Forecasts To 2022 - Product Image

Vaccine Market by Technology & Types, Various Classes & Indications - Global Forecasts To 2022

  • ID: 2623206
  • August 2013
  • Region: Global
  • 195 Pages
  • Markets and Markets

FEATURED COMPANIES

  • Aduro Biotech
  • Antigen Express, INC
  • Genticel
  • Immunobiology LTD
  • Merck & CO, INC
  • Pfizer, INC
  • MORE

'Vaccine Market - By Technology & Types, Trend Analysis By Various Classes - Live / Attenuated, Subunit, Toxoid, Conjugate, DNA, Recombinant Vector, Synthetic, Dentritic Vaccines And By Indications - Infectious Diseases, Cancer, Allergy, Diabetes, Cardiovascular Disease With Market Landscape Analysis - Global Forecasts To 2022'

The vaccine technology market is an established segment and is widely accepted as an indispensable division of the healthcare industry. It is poised to grow rapidly by addressing the following issues: emerging infectious agents, various types of cancer, allergies, cardiovascular diseases, diabetes, smoke cessation, and neurodegenerative disorders. The global vaccine market is estimated at $32.05 billion in 2013 and is expected to reach $84.44 billion by 2022.

In general, the vaccine technology market is largely perceived negatively as a low-profit venture owing to the domination of top five companies, namely, Sanofi (France), Glaxo Smithkline (U.K.), Merck (U.S.), Pfizer (U.S.), and Novartis (Switzerland). Furthermore, a strong patent portfolio and the need for large investments towards vaccine development have limited the scope of entry for READ MORE >

FEATURED COMPANIES

  • Aduro Biotech
  • Antigen Express, INC
  • Genticel
  • Immunobiology LTD
  • Merck & CO, INC
  • Pfizer, INC
  • MORE

1 Introduction
1.1 Key Take-Aways
1.2 Report Scope
1.3 Report Segmentation
1.4 Research Methodology
1.5 Key Data Points From Secondary And Primary Sources
1.6 Logical Assumptions In This Study Based On Reliable Sources

2 Executive Summary

3 Technology Snapshot (Page No. - 31)
3.1 Technology – Introduction
3.2 Technology – Evolution
3.3 Technology Segmentation
3.4 Technology Trends – By Class
3.4.1 Adjuvants
3.5 Key Vaccine Products In The Market
3.6 Technology Roadmap

4 Vaccine Research Portfolio
4.1 Global Research Portfolio – Research And Development Network
4.2 Emerging Approaches To Vaccine Developments
4.3 Key Research Centres

5 Value Chain Analysis
5.1 Overview
5.2 Cold Chain Management
5.3 Key Stakeholders
5.4 Gap Analysis
5.5 Porters Five Force Analysis

6 Market Landscape
6.1 Global Vaccine Technologies Market, Global Forecasts (2013 – 2022)
6.1.1 Global Vaccine Technologies Market, By Geography, 2012 – 2022
6.1.2 Vaccine Technologies Market Segmentation
6.1.3 Market Dynamics
6.1.3.1 Drivers
6.1.3.2 Restraints
6.1.3.3 Opportunities, Threats And Challenges
6.2 Global Vaccine Technologies Market, By End-User, 2012-2022
6.2.1 Global Vaccine Technologies Market Share, By End-User, 2012 – 2022
6.2.2 Paedriatic Vaccine Market, By Geography
6.2.3 Global Paedriatic Vaccine Market Share, By Geography
6.2.4 Global Adult Vaccine Market, By Geography
6.2.5 Global Adult Vaccine Market Share, By Geography
6.3 Global Vaccine Technologies Market, By Type, 2012-2022
6.3.1 Global Vaccine Technologies Market Share, By Type, 2012-2022
6.3.2 Global Preventive Vaccine Market, By Geography, 2012 – 2022
6.3.3 Global Preventive Vaccine Market Share, By Geography, 2012-2022
6.3.4 Global Therapeutic Vaccine Market, By Geography, 2012 – 2022
6.3.5 Global Therapeutic Vaccine Market Share, By Geography, 2012 – 2022
6.4 Global Vaccine Technologies Market, By Class, 2012 – 2022
6.4.1 Global Vaccine Technologies Market Share, By Class, 2012-2022
6.4.2 Live/Attenuated Vaccine Market, By Geography
6.4.2.1 Live/ Attenuated Vaccine Market Share, By Geography
6.4.3 Toxoid Vaccine Market, By Geography
6.4.3.1 Toxoid Vaccine Market Share, By Geography
6.4.4 Conjugate Vaccine Market, By Geography
6.4.4.1 Conjugate Vaccine Market Share, By Geography
6.4.5 Sub-Unit Vaccine Market, By Geography
6.4.6 Recombinant Vector Vaccine Market, By Geography, 2012 – 2022
6.4.7 Dna Vaccine Market, By Geography, 2012 – 2022
6.4.8 Synthetic Vaccine Market, By Geography, 2012 – 2022
6.4.8.1 Synthetic Vaccine Market Share, By Geography, 2012 – 2022
6.4.9 Dentritic Vaccine Market, By Geography, 2012 – 2022
6.5 Vaccine Market, By Disease Indication (2012 - 2022)
6.5.1 Infectious Disease Vaccine Market, By Geography
6.5.2 Cancer Vaccine Market, By Geography
6.5.3 Allergy Vaccine Market, By Geography
6.5.4 Others Vaccine Market, By Geography, 2012 – 2022
6.5.5 Others Potential Market, By Geography, 2016 – 2022

7 Technology Adoption
7.1 Factors That Drive Adoption Of Vaccine Technologies (Demand And Supply Side Analysis)
7.2 North America – U.S. & Canada
7.3 Europe – U.K, Germany, France, Italy
7.4 Asia – China, India
7.5 RoW – Australia & Africa

8 Investment Analysis
8.1 Investor Network
8.2 Investment Funding Analysis
8.3 Top Funding Organizations

9 Competitive Landscape
9.1 Competitive Landscape Analysis – Overview
9.2 Key Acquisitions/Partnerships/Agreements/Collaborations (2012 – 2013)
9.3 Vaccine Candidates In Pipeline – Allergy
9.4 Vaccine Candidates In Pipeline – Cancer
9.5 Vaccine Candidates In Pipeline – Infectious Diseases
9.6 Vaccine Candidates In Pipeline – Others

10 Regulatory Landscape
10.1 Regulatory Landscape – Overview
10.2 Regulations – Geographic

11 Patent Analysis
11.1 Patent Analysis – Overview
11.2 Patent Analysis By Company

12 Analyst Recommendations
12.1 Introduction
12.2 Technology Management Strategies

13 Company Profiles
13.1 Novartis AG
13.2 Glaxo Smithkline PLC
13.3 Merck & CO., INC.
13.4 Sanofi
13.5 Pfizer, INC.
13.6 Antigen Express, INC.
13.7 Aduro Biotech
13.8 Genticel
13.9 Biondvax Pharmaceuticals LTD
13.10 Immune Targeting Systems (ITS)
13.11 Prokarium
13.12 Immunobiology LTD
13.13 Liquidia Technologies
13.14 Alphavax
13.15 Bavarian Nordic

14 Appendix (Page No. - 177)
Inter-Country Comparison Of Mortality For Selected Cause Of Death

List Of Tables (22 Tables)

Table 1 Vaccine Technologies Market, By Geography, 2012 – 2022 ($Billion)
Table 2 Global Vaccine Technologies Market, By End-User, 2012 – 2022 ($Billion)
Table 3 Paedriatic Vaccine Market, By Geography, 2012 – 2022 ($Billion)
Table 4 Adult Vaccine Market, By Geography, 2012 – 2022 ($Billion)
Table 5 Global Vaccine Technologies Market, By Type, 2012 – 2022 ($Billion)
Table 6 Global Preventive Vaccine Market, By Geography, 2012 – 2022 ( $Billion)
Table 7 Therapeutic Vaccine Market, By Geography, 2012 – 2022 ($Billion)
Table 8 Global Vaccine Technologies Market, By Technology Class, 2012 – 2022 ($Billion)
Table 9 Global Live Vaccine Market, By Geography, 2012-2022 ($Billion)
Table 10 Toxoid Vaccine Market, By Geography, 2012 – 2022 ($Billion)
Table 11 Conjugate Vaccine Market, By Geography, 2012 – 2022 ($Billion)
Table 12 Subunit Vaccine Market, By Geography, 2012 – 2022 ($Billion)
Table 13 Recombinant Vector Vaccine Market, By Geography, 2012 – 2022 ($Billion)
Table 14 Dna Vaccine Market, By Geography, 2012 – 2022 ($Billion)
Table 15 Synthetic Vaccine Market, By Geography, 2012 – 2022
Table 16 Dentritic Vaccine Market, By Geography, 2017 – 2022 ($Billion)
Table 17 Global Vaccine Market, By Disease Indication, 2012 – 2022 ($Billion)
Table 18 Infectious Disease Vaccine Market, By Geography, 2012 – 2022 ($Billion)
Table 19 Cancer Vaccine Market, By Geography, 2012 – 2022 ($Billion)
Table 20 Allergy Vaccine Market, By Geography, 2012 – 2022 ($Billion)
Table 21 Others (Cardiovascular Disease, Diabetes, Smoke Cessation) Potential Market,By Geography, 2016 – 2022 ($Billion)
Table 22 Revenue Of Top 5 Companies

List Of Figures (53 Figures)

Figure 1 Global Vaccine Market, 2007 – 2012 ($Billion)
Figure 2 Global Vaccine Technologies Market,2012 – 2022 ($Billion)
Figure 3 Porter’s Value Chain Analysis
Figure 4 Global Vaccine Market, 2007 – 2012 ($Billion)
Figure 5 Global Vaccine Technologies Market, 2013 – 2022 ($Billion)
Figure 6 Vaccine Technologies Market, By Geography, 2012 – 2022 ($Billion)
Figure 7 Vaccine Technologies Market Share, By Geography, 2012 – 2022
Figure 8 Global Vaccine Technologies Market, By End-User, 2012 – 2022 ($Billion)
Figure 9 Global Vaccine Technologies Market Share, By End-User, 2012 – 2022
Figure 10 Paedriatic Vaccine Market, By Geography, 2012 – 2022
Figure 11 Paedriatic Vaccine Market Share, By Geography, 2012 – 2022
Figure 12 Adult Vaccine Market, By Geography, 2012 – 2022
Figure 13 Adult Vaccine Market Share, By Geography, 2012 – 2022
Figure 14 Global Vaccine Technologies Market, By Type, 2012 – 2022
Figure 15 Global Vaccine Technologies Market Share, By Type, 2012 – 2022
Figure 16 Preventive Vaccine Market, By Geography, 2012 – 2022
Figure 17 Preventive Vaccine Market Share, By Geography, 2012 – 2022
Figure 18 Therapeutic Vaccine Market, By Geography, 2012 – 2022
Figure19 Therapeutic Vaccine Market Share, By Geography, 2012 – 2022
Figure 20 Global Vaccine Technologies Market, By Technology Class, 2012 – 2022 ($Billion)
Figure 21 Global Vaccine Technologies Market Share, By Class, 2012 - 2022
Figure 22 Live/Attenuated Vaccine Market, By Geography, 2012 – 2022
Figure 23 Live/Attenuated Vaccine Market Share, By Geography, 2012 – 2022
Figure 24 Toxoid Vaccine Market, By Geography, 2012 – 2022
Figure 25 Toxoid Vaccine Market Share, By Geography, 2012 – 2022
Figure 26 Conjugate Vaccine Market, By Geography, 2012 – 2022
Figure 27 Conjugate Vaccine Market Share, By Geography, 2012 – 2022
Figure 28 Subunit Vaccine Market, By Geography, 2012 – 2022 ($Billion)
Figure 29 Sub-Unit Vaccine Market, By Geography, 2012 – 2022
Figure 30 Recombinant Vector Vaccine Market, By Geography, 2012-2022
Figure 31 Recombinant Vector Vaccine Market Share, By Geography, 2012 – 2022
Figure 32 Dna Vaccine Market, By Geography, 2012 – 2022 ($Billion)
Figure 33 Dna Vaccine Market, By Geography, 2012 – 2022
Figure 34 Synthetic Vaccine Market, By Geography, 2012 – 2022
Figure 35 Synthetic Vaccine Market Share, By Geography, 2012 – 2022
Figure 36 Dentritic Vaccines, By Geography, 2012 – 2022
Figure 37 Dentritic Vaccine Market Share, By Geography, 2012 – 2022
Figure 38 Global Vaccine Market, By Disease Indication, 2012 – 2022
Figure 39 Global Vaccine Market Share, By Disease Indication, 2012 – 2022
Figure 40 Infectious Disease Vaccine Market, By Geography, 2012 – 2022
Figure 41 Infectious Disease Vaccine Market Share, By Geography, 2012 – 2022
Figure 42 Cancer Vaccine Market, By Geography, 2012 – 2022 ($Billion)
Figure 43 Cancer Vaccine Market, By Geography, 2012 – 2022
Figure 44 Allergy Vaccine Market, By Geography, 2012 – 2022
Figure 45 Allergy Vaccine Market Share, By Geography, 2012 – 2022
Figure 46 Others (Cardiovascular Disease, Diabetes, Smoke Cessation) Potential Market,By Geography, 2016 – 2022 ($Billion)
Figure 47 Others (Cardiovascular Disease, Diabetes, Smoke Cessation) Potential Market,By Geography, 2016 – 2022
Figure 48 Global Vaccine Technologies Market,By Geography, 2012 – 2022
Figure 49 Vaccine- Investor Network
Figure 50 Global Vaccine Market Share,By Key Player, 2013
Figure 51 Regulatory Approval Process
Figure 52 Total Patents Filed Between 2008 – 2013
Figure 53 Patent Analysis By Companies (2008 – 2012)

FEATURED COMPANIES

  • Aduro Biotech
  • Antigen Express, INC
  • Genticel
  • Immunobiology LTD
  • Merck & CO, INC
  • Pfizer, INC
  • MORE

The global vaccine technology market is anticipated to reach around $84 billion by 2022, growing at a CAGR of 11.36%. The vaccine market is divided by technology class (Live/Attenuated, Toxoid, Conjugate, Sub-Unit, Recombinant Vector, DNA, Synthetic, and Dentritic Vaccines), types (Preventive and Therapeutic), end users (Pediatric and Adult), disease indication (Infectious Diseases, Cancer, Allergies, and Others – Diabetes, Cardiovascular Diseases), and geography (North America, Europe, Asia, and Rest of the World). Furthermore, each technology class, type, end user, and disease indication segment is broken down by geography, with exhaustive revenue analysis for the entire forecast period. Of the above mentioned disease indication segments, infectious disease vaccines are the largest revenue segment; however, cancer vaccines will be the fastest-growing segment with the highest CAGR.

The potential growth of the market is attributed towards therapeutic vaccines, allergy vaccines, and emerging-disease vaccines. Improved understanding of immunology, new technological breakthroughs in the development of a new class of vaccines, namely, recombinant vector vaccines, DNA vaccines, and dendritic vaccines coupled with excellent distribution channels are propelling the growth of this market. Furthermore, a large population base in emerging economies and a high prevalence of diseases is driving the market, which is expected to remain consistent in the coming years.

Largely popular as the biological preparation exclusively for the prevention of diseases, vaccines are now emerging as therapeutic agents for improving the immune system. This is adding a new dimension to the vaccine industry, opening doors for the treatment of various ailments, especially cancer, cardiovascular disease, diabetes, and smoke cessation. These opportunities have also paved the way for the entry of new companies and for the development of newer technology platforms. Furthermore, new emerging approaches to vaccine development such as reverse vaccinology, personalized vaccinomics, and systems vaccinomics are paving the way for the development of new effective vaccines capable of addressing current and emerging infectious diseases and cancers.

North America (42%) is a significant contributor, followed by Europe (36%), due to the highly structured healthcare reimbursement policies and the high purchasing power of costly vaccines. The new markets for vaccine are expected to grow at a vigorous pace in emerging economies such as China, India, and other regions in Asia-Pacific and untapped markets in Europe due to their growing GDP, healthcare costs, and rising demand for safe and cost-effective diagnostics and therapeutics.

The key players in this market are Novartis (Switzerland), Glaxo Smithkline (U.K.), Merck (U.S.), Sanofi (France), Pfizer (U.S.), Antigen Express, Inc. (U.S.), Aduro Biotech (U.S.), Genticel (France), Biondvax (Israel), Immune Targeting Systems (U.K.), Prokarium (U.K.), Immunobiology Ltd. (U.K.), Liquidia Technologies (U.S.), Alphavax (U.S.), and Bavarian Nordic (Denmark).

- Aduro Biotech
- Alphavax
- Antigen Express, INC
- Bavarian Nordic
- Biondvax Pharmaceuticals LTD
- Genticel
- Glaxo Smithkline PLC
- Immune Targeting Systems (ITS)
- Immunobiology LTD
- Liquidia Technologies
- Merck & CO, INC
- Novartis AG
- Pfizer, INC
- Prokarium
- Sanofi

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos